|
1p21.3 microdeletion syndrome
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability.
|
22003227 |
2011 |
|
1p21.3 microdeletion syndrome
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder.
|
21114665 |
2011 |
|
Abnormal eating behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of vision
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute lymphocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The authors conclude that patients carrying the c.85T>C C allele have an increased risk of developing acute lymphoblastic leukemia and have inferior outcome, and that DPYD c.85T>C can be used as a guide for individualized treatment and the decision to utilize 5-fluorouracil in acute lymphoblastic leukemia patients.
|
28618970 |
2017 |
|
Acute lymphocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
|
26846104 |
2016 |
|
Acute respiratory failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the efficacy of PMX-DHP therapy for acute respiratory failure in patients with RPIPs, when compared with a historical control receiving conventional treatment without PMX-DHP.
|
28554260 |
2017 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
TS and DPD expression levels were higher in tumor tissues, and TS expression levels were significantly lower in adenocarcinomas than those in other subtypes.
|
28835573 |
2017 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The levels of dihydropyrimidine dehydrogenase and thymidine phosphorylase mRNA in PPC showed a similar tendency to those in SCC, in contrast to AC.
|
26031756 |
2015 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
DPD immunopositive cases were more frequently observed in adenocarcinoma, in females, and in nonsmokers.
|
24405586 |
2014 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Neuroendocrine carcinomas show characteristic patterns of expression for 5-FU-related enzymes, including low DPD mRNA and protein level and high TS mRNA level compared with adenocarcinomas.
|
21062732 |
2010 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
Although both TS and DPD activities showed a tendency to be high for adenocarcinoma, there was no significant difference between TS and/or DPD activities and any clinical findings (age, gender, stage and histological type).
|
15868929 |
2005 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The relative gene expression value of DPD was significantly greater in adenocarcinomas than those in squamous cell carcinomas, 2.33 +/- 1.22 versus 1.50 +/- 1.20 (P = 0.01).
|
19015148 |
2009 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
LHGDN |
The ratio of the TP level to DPD level in tumor tissue was higher in squamous cell carcinoma than in adenocarcinoma.
|
16969493 |
2006 |
|
Adenocarcinoma in Situ
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Adenocarcinoma in situ showed significantly higher DPD mRNA levels and more EGFR mutation frequency than other histological types (P < .05).
|
24405586 |
2014 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TS, TP and DPD expression levels were investigated by real-time quantitative RT-PCR on RNA extracts from formalin-fixed and paraffin-embedded tissues of 55 patients with colon adenocarcinoma.
|
20387074 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
|
24405586 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas.
|
19015148 |
2009 |
|
Adenocarcinoma of lung (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
|
25573239 |
2015 |
|
Adenocarcinoma of rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
This work is intended to study the effect of preoperative capecitabine and radiotherapy treatment on the levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) mRNAs in rectal carcinoma.
|
17688376 |
2007 |
|
Adult Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we have established that increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(<i>N</i>-alkylpyridinium)-1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma) cell lines, as well as the estimated basal cytotoxicity.
|
30871041 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, this study emphasizes the possible potential and therapeutic role of DHP-8 in skin and liver cancer.
|
30203236 |
2018 |
|
Adult Solid Neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
5-Fluorouracil (5-FU), the mainstay of solid tumor chemotherapy over the past 40 years, induces grade III-IV toxicities in up to 15% of patients with polymorphisms in the dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), and methylenetetrahydrofolate reductase (MTHFR) genes.
|
24434920 |
2015 |
|
Advanced breast cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The aim of this prospective pilot study was to analyze the effect of TS, MTHFR, and DPD gene polymorphisms on toxicity and efficacy in advanced breast cancer patients receiving capecitabine as monotherapy.
|
17000685 |
2006 |
|
Advanced breast cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and toxicity in advanced breast cancer patients receiving capecitabine.
|
28481884 |
2017 |